Eli Lilly (LLY) +7.4% premarket after two large studies show its experimental Alzheimer’s...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Eli Lilly (LLY) +7.4% premarket after two large studies show its experimental Alzheimer’s treatment slowed the decline of cognition in some patients, although it failed to meet its primary goals. The finding that the drug slowed the worsening of mental loss in mild to moderate patients wasn’t expected by analysts, who had given the drug a less than 20% chance of showing a benefit.